PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of "Hold" by Analysts

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has received an average rating of "Hold" from the sixteen brokerages that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating, six have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $37.64.

A number of research firms recently commented on PTCT. Cantor Fitzgerald reiterated an "overweight" rating and issued a $64.00 target price on shares of PTC Therapeutics in a research report on Tuesday. Barclays boosted their target price on PTC Therapeutics from $25.00 to $31.00 and gave the stock an "equal weight" rating in a research report on Friday, August 9th. UBS Group began coverage on PTC Therapeutics in a research report on Monday, August 26th. They issued a "buy" rating and a $47.00 target price on the stock. Robert W. Baird began coverage on PTC Therapeutics in a research report on Wednesday, September 4th. They issued an "outperform" rating and a $44.00 target price on the stock. Finally, Baird R W upgraded PTC Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 4th.

PTC Therapeutics Price Performance

Shares of NASDAQ PTCT traded up $0.48 during mid-day trading on Friday, reaching $36.64. The company's stock had a trading volume of 1,153,878 shares, compared to its average volume of 854,676. The firm has a market capitalization of $2.82 billion, a PE ratio of -4.77 and a beta of 0.64. The stock has a fifty day moving average of $33.41 and a two-hundred day moving average of $32.42. PTC Therapeutics has a 52 week low of $17.53 and a 52 week high of $40.69.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing analysts' consensus estimates of ($1.00) by ($0.16). The firm had revenue of $186.70 million during the quarter, compared to analysts' expectations of $192.12 million. Analysts anticipate that PTC Therapeutics will post -5.09 EPS for the current fiscal year.

Insider Transactions at PTC Therapeutics

In other news, CFO Pierre Gravier sold 2,269 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $34.02, for a total value of $77,191.38. Following the sale, the chief financial officer now directly owns 53,531 shares in the company, valued at $1,821,124.62. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP grew its stake in PTC Therapeutics by 4.0% in the fourth quarter. Wellington Management Group LLP now owns 9,816,603 shares of the biopharmaceutical company's stock worth $270,546,000 after purchasing an additional 380,415 shares in the last quarter. Vanguard Group Inc. boosted its position in PTC Therapeutics by 6.5% during the 1st quarter. Vanguard Group Inc. now owns 9,369,014 shares of the biopharmaceutical company's stock valued at $272,545,000 after acquiring an additional 568,171 shares in the last quarter. RTW Investments LP boosted its position in PTC Therapeutics by 2.6% during the 4th quarter. RTW Investments LP now owns 7,423,970 shares of the biopharmaceutical company's stock valued at $204,605,000 after acquiring an additional 188,774 shares in the last quarter. Armistice Capital LLC boosted its position in PTC Therapeutics by 2.9% during the 2nd quarter. Armistice Capital LLC now owns 6,962,227 shares of the biopharmaceutical company's stock valued at $212,905,000 after acquiring an additional 198,227 shares in the last quarter. Finally, Cowen AND Company LLC boosted its position in PTC Therapeutics by 0.8% during the 2nd quarter. Cowen AND Company LLC now owns 3,756,469 shares of the biopharmaceutical company's stock valued at $114,873,000 after acquiring an additional 30,843 shares in the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.